Form 4 for RPRX Royalty Pharma plc
Accepted 2023-06-28 00:00:00 ET · period of report 2023-06-28 · accession 0001209191-23-040024 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2023-06-28 | 2023-06-28 | RPRX | Legorreta Pablo G. | CEO, COB, Dir, 10% | P - Purchase | $29.51 | +130.0K | 600.0K | +28% | +$3.84M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A ordinary shares | 2023-06-28 | P | A | 130,000 | $29.51 | 600,000 | I By Legorreta 2023 SR Trust | — | — | (F2) The price reported in Column 4 is a weighted average price. The reported securities were purchased in multiple transactions at prices ranging from $29.40 to $29.60. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within such range. |